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ABSTRACT 
Background: Obesity is closely related to development of insulin resistance and 
dyslipidemia. Intrinsic properties of adipose tissue are also of great importance for obesity 
related comorbidity. The aim of this thesis was to gain further knowledge of adipose depot 
specific effects of how fat cell size and lipolysis, as well as removal of a large portion of the 
visceral fat depot, affect metabolic risk.  
Methods: All subjects were from a cohort of 81 obese women undergoing gastric bypass 
operation. Study I and study III were cross-sectional studies using baseline data, whereas 
study II and IV were longitudinal studies which also included an examination two years post-
surgery. Insulin sensitivity was evaluated with hyperinsulinemic euglycemic clamp. 
Subcutaneous and visceral fat biopsies were obtained to determine mean fat cell size and 
lipolysis. 
Results: Study I showed that subcutaneous fat cell size correlated with insulin sensitivity  
(r= -0.40 p= 0.004) and visceral fat cell size correlated with dyslipidemia (r=0.32-0.38 p= 
0.0006-0.003). Subjects with combined hyperplasia (many small fat cells) in both 
subcutaneous and visceral fat depots had a favorable metabolic profile compared to subjects 
with combined hypertrophy (few but large fat cells) (p= 0.0001-0.02). 
Study II focused on changes in fat cell size and insulin sensitivity following weight reduction 
induced by bariatric surgery in obese women. Changes in subcutaneous fat cell size 
correlated with improved insulin sensitivity independently of changes in subcutaneous fat 
mass (r=0.32 p= 0.04).  
Study III investigated depot specific relations between lipolysis and cardiovascular risk 
factors. Visceral but not subcutaneous fat cell lipolysis correlated with several cardiovascular 
risk factors including insulin resistance, high plasma triglycerides and blood pressure (r= 
0.28-0.44 p= 0.0001-0.02). Visceral fat cell lipolysis was also increased in subjects with 
metabolic syndrome (F= 8.3 p= 0.005).  
Study IV, designed as a randomized double blind controlled trial, investigated the 2-year 
effects of omentectomy in conjunction with gastric bypass operation on insulin sensitivity 
and the lipid profile. Eighty-one subjects were included in the study and 62 were re-examined 
two years post-surgery. Omentectomy did not give any additional positive metabolic effects, 
neither in the primary outcome measure insulin sensitivity (p= 0.54), nor the secondary 
outcome measures such as lipid status or weight reduction (p= 0.17-0.98).   
Conclusion: The studies in this thesis highlight that intrinsic factors of adipose tissue, such as 
fat cell size and lipolysis, independently of fat mass, are important for metabolic 
complications in obesity. A mere removal of a substantial part of the visceral fat depot does 
not enhance improved metabolic outcome after gastric bypass operation, suggesting that a 
metabolic change in adipose tissue and changes in fat cell size are important to achieve 
positive effects of fat mass reduction. 
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1 INTRODUCTION 
1.1 OBESITY AND THE METABOLIC SYNDROME 
Obesity is a major risk factor for development of type 2 diabetes, dyslipidemia and 
hypertension which in turn can lead to cardiovascular disease. Approximately 35 % of adults 
in the United States were considered obese (body mass index, BMI ≥ 30 kg/m2) in 20121 and 
although less common in Sweden (14%),
2
 obesity related comorbidities constitute a large and 
growing problem in Swedish healthcare.
3
 However, as many as 30% of obese individuals do 
not develop obesity related complications.
4
 Body fat distribution as well as altered adipose 
tissue function such as low grade inflammation and impaired lipolysis seem to play a role in 
pathogenesis.
4
  
Already in 1956 Jean Vague acknowledged the importance of body fat distribution in 
development of metabolic complications.
5
 An accumulation of fat in the upper body, more 
commonly seen in men and therefore called android fat mass, was more strongly associated 
with diabetes and arteriosclerosis compared to the more benign lower body fat accumulation 
often seen in women (gynoid fat). Upper body fat mass has two main depots, fat under the 
skin (subcutaneous adipose tissue) and fat around the intestines (visceral adipose tissue). 
Studies have shown that visceral adipose tissue is, independently of total fat mass, an 
additional risk factor for hypertension, insulin resistance and type 2 diabetes as well as 
cardiovascular disease.
6-8
 The visceral fat depot consists of the greater omentum, mesenteric-, 
perirenal- and gonadal fat whereof the greater omentum is the largest part. The omentum is 
the only visceral depot that can be removed without medical risk.  
The term “metabolic syndrome” is used to describe a metabolic state characterized by obesity 
together with several obesity related complications. The exact definition of what constitutes 
the metabolic syndrome has changed slightly over the years but the cornerstones today are 
central obesity, dyslipidemia, hyperglycemia and hypertension according to the International 
Diabetes Federation.
9
 The more risk factors a person have the higher the risk of developing 
cardiovascular disease.  
Several factors have been identified explaining why different fat depots exhibit different 
associations with cardiovascular risk factors. The anatomical proximity of visceral adipose 
tissue to the liver is such a factor. Björntorp forged the expression “portal theory” in 1990 
when he described that the location of visceral adipose tissue, draining secreted factors into 
the portal vein leading directly to the liver, has an impact on liver induced insulin 
resistance.
10
 Regional differences in the ability of adipose tissue to store free fatty acids as 
triglycerides (lipogenesis), variations in the ability to break down triglycerides into free fatty 
acids and glycerol (lipolysis), adipokine secretion, inflammation or differences in fat cell size 
are some adipose characteristics that also can be part of the explanation. 
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1.2 GASTRIC BYPASS OPERATION  
Treating obesity has been proven difficult, and even though weight reduction can be achieved 
by exercise and/or changes in diet, the best validated method to accomplish a substantial 
sustained weight reduction is bariatric surgery.
11-14
 Roux en Y gastric bypass operation 
(RYGB) is the most common method of bariatric surgery in Sweden. RYGB has been shown 
to improve metabolic control and even lead to remission of type 2 diabetes,
13, 15, 16
 and 
reduced cardiovascular events.
17
   
During a RYGB, the ventricle and about 120 cm of the smaller intestine is bypassed and a 
small gastric pouch is created distal to the esophagus and reconnected to the small intestine 
(Figure 1), resulting in restrictive and malabsorptive effects.  
 
Figure 1. 
Gastric bypass operation. Source: Dirksen et al Diabetologia18. 
In addition, it has been shown that RYGB also alters the hormonal response following a meal 
intake. For example, RYGB leads to increased levels of GLP-1 and peptide YY and 
decreased levels of ghrelin. These alterations interestingly seem to affect both satiety and 
hunger as well as food preference.
19-21
 In addition to this, RYGB leads to increased hepatic 
and muscle insulin sensitivity and increased insulin secretion independently of weight 
reduction, probably due to hormonal changes.
22, 23
 RYGB is more effective for weight 
reduction than ventricular restriction such as gastric banding (a different kind of bariatric 
surgery).
24
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1.3 INSULIN  
Insulin is a hormone with strong anabolic effects that is produced in the β-cells on the isles of 
Langerhans of the pancreas. Several factors that stimulate secretion of insulin are depicted in 
Figure 2 such as increasing plasma glucose, rises in amino acid levels and several 
gastrointestinal hormones (incretins). In the liver, insulin stimulates glycogen production and 
inhibits glycogenolysis and release of glucose into the blood stream.  
Insulin also has effects on fatty acid metabolism by increasing lipoprotein lipase activity 
which leads to increased uptake of free fatty acids (FFA) in adipocytes and in turn increased 
triglyceride synthesis. It is also a potent anti-lipolytic hormone by inhibiting the effect of 
hormone sensitive lipase, the rate limiting enzyme of triglyceride catabolism (Figure 2). 
Insulin inhibits glucose output from the liver and stimulates glucose uptake, primarily in 
muscle but also in adipose tissue. FFA in plasma inhibits the insulin mediated uptake of 
glucose into muscles and also phosphorylation of glucose that in turn leads to reduction of 
glycogen synthesis and glucose oxidation.
25, 26
  
 
 
Figure 2. 
Function of insulin and pathology behind insulin resistance and insufficient insulin secretion. FFA = free fatty acids, 
IGF-1 = insulin-like growth factor 1. GLP-1   = stimulation = inhibition = increase   
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Glucose and insulin levels in the body are tightly regulated to maintain homeostasis. In the 
fasting state, insulin secreted from the β-cells regulates glucose release from glycogen levels 
in the liver so it is equal to glucose uptake in peripheral tissues thereby maintaining the same 
blood glucose levels.  
Hyperglycemia occurs if the β-cells are unable to secrete sufficient amounts of insulin which 
can manifest itself as impaired fasting glucose and/or impaired glucose tolerance following a 
meal. These two conditions often precede the development of type 2 diabetes.
27
  
The metabolic answer following insulin stimulation in a subject or a target tissue is a measure 
of insulin sensitivity and the term insulin resistance can be used if the metabolic answer is 
inadequately low. Insulin resistance can occur in both the liver and/or peripheral tissues such 
as muscle and fat. Different factors that influence and cause insulin resistance as well as β-
cell dysfunction are listed in Figure 2. 
1.3.1 Insulin sensitivity measurements 
Insulin sensitivity in vivo can be assessed in several ways that highlight different aspects of 
insulin sensitivity. In this thesis we have used an indirect method, homeostasis model 
assessment of insulin resistance (HOMA-IR), and a direct method, euglycemic 
hyperinsulinemic clamp to determine insulin sensitivity. Although important, we have not 
evaluated the β-cell function in this thesis.   
1.3.1.1 Hyperinsulinemic euglycemic clamp 
Hyperinsulinemic euglycemic clamp is considered to be the gold standard technique to 
evaluate insulin sensitivity. During a hyperinsulinemic clamp a fixed insulin infusion (based 
on weight or body surface area) induces a hyperinsulinemic state. The blood glucose levels 
are then maintained (clamped) at a euglycemic level (4.5-5.5 mmol/l) with an exogenous 
glucose infusion. The rate of exogenous glucose infusion is then equal to glucose disposal 
rate, i.e. insulin sensitivity. An insulin sensitive subject will require higher rates of glucose 
infusion compared to a subject who is insulin resistant. During the induced hyperinsulinemia, 
almost all infused glucose is taken up by skeletal muscle (80-90%) and therefore the 
hyperinsulinemic euglycemic clamp reflects primarily skeletal muscle insulin sensitivity.
28
 It 
is important that the insulin infusion is sufficiently high to suppress hepatic glucose 
production for a correct assessment of muscle insulin sensitivity (if hepatic glucose 
production is not suppressed the “true” glucose disposal rate will be higher than the obtained 
value).   
1.3.1.2 Homeostasis model assessment of insulin resistance 
Homeostasis model assessment of insulin resistance (HOMA-IR) is a mathematical model 
developed by Matthews and colleagues to assess insulin resistance and β-cell function.29 The 
model uses fasting state plasma insulin and plasma glucose to determine insulin resistance. 
As discussed above, in the fasting state, glucose and insulin levels are highly dependent on 
hepatic glucose production. Therefore, HOMA-IR reflects hepatic insulin resistance rather 
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than the skeletal muscle insulin sensitivity measured with hyperinsulinemic euglycemic 
clamp.  
1.4 ADIPOSE TISSUE 
Adipose tissue is composed mainly of adipocytes and these are surrounded by the stroma 
vascular fraction that comprises a large variety of cells (approximately 50% of all the tissue 
cells) such as different pre-cursor cells, immune cells, vascular cells and fibroblasts together 
with extra cellular proteins.
30
   
1.4.1 Fat cell size 
In 1968 Hirsch and Gallian described a method for isolation and determination of human fat 
cell size and many elegant studies were performed on adipose tissue in the 1960ies and 
1970ies.
31
 Fat cell size was found to correlate with obesity and serum insulin.
32, 33
 The term 
hypertrophy was starting to be used to describe adipose tissue with large and few fat cells 
whereas the term hyperplasia was used to describe an adipose tissue characterized by many 
but small fat cells. Björntorp and Sjöström showed that in normal weight subjects fat cell size 
increases with increasing body weight, and in subjects with a higher amount of body fat there 
is both an increase in fat cell size and number.
33
 Many of the older studies were small and did 
not describe human visceral adipose tissue. The determination of total fat cell number also 
demands an estimation of fat mass, which was previously hard to perform.  
In the last decades, new methods have been developed for determination of total fat mass and 
fat mass in different depots. The realization that adipocytes are hormonally active have led to 
new studies on the impact of fat cell size. In 2008, our group showed that about 10% of 
adipocytes are renewed annually and in the same publication we also confirmed a curve-
linear relationship between fat mass and fat cell size.
34
 This curve could be used to get a 
numerical value, which we called morphology value, illustrating to what extent a subjects 
adipose tissue is hypertrophic (positive value) or hyperplastic (negative value). Our group 
later showed that the renewal of fat cells in subjects with hypertrophic adipose tissue had 
70% lower turnover (in absolute numbers) than in subjects with hyperplastic adipose tissue 
and that hypertrophy is linked to a disadvantageous metabolic profile.
35
 Adipose tissue 
morphology has been shown to correlate positively with tumor necrosis factor α (TNFα), a 
potent inducer of inflammation and also involved in metabolic dysregulation in adipose 
tissue.
36
  
1.4.2 Fat cell metabolism 
The ability to degrade triglycerides (lipolysis) and re-esterify free fatty acids to triglycerides 
are important functions of adipose tissue. Both functions occur at the same time and 
depending on the nutritional status, one of these functions prevails over the other resulting in 
release of FFA from the adipocyte or storage of FFA as triglycerides in lipid droplets inside 
the adipocyte.
37, 38
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1.4.2.1 Triglyceride synthesis in adipocytes - lipogenesis 
Fatty acids are transported in the blood as triglycerides contained in different lipoproteins. 
Following a meal dietary lipids absorbed from the gut are transported in chylomicrons. 
Endogenous lipids are transported to various locations in the form of very low density 
lipoproteins (VLDL) produced by the liver. The various lipoproteins reach the adipocyte 
through the blood stream. Adipocytes secrete the enzyme lipoprotein lipase, which binds to 
the endothelium in the capillaries and hydrolyses triglycerides from the lipoproteins into free 
fatty acids and glycerol. This enables the FFA to be transported into the adipocyte where they 
together with glucose serves as a substrate in the process of re-esterification in to TG 
subsequently stored in the adipocyte. Both lipoprotein lipase enzyme activity and glucose 
uptake are stimulated by insulin.  
1.4.2.2 Breakdown of triglycerides in adipocytes - lipolysis 
During lipolysis, each triglyceride molecule is broken down in a stepwise fashion into three 
fatty acids and one glycerol molecule (Figure 3). The first rate limiting step in lipolysis is the 
conversion of triglycerides to diacylglycerol (DG) and one FFA molecule. This reaction is 
catalyzed by adipose triglyceride lipase (ATGL), also called desnutrin, and to a less extent 
hormone sensitive lipase (HSL). ATGL seems to have larger impact on basal lipolysis 
whereas HSL is important under both basal and stimulated conditions.
39, 40
 HSL is also 
responsible for the second rate limiting step in lipolysis, conversion of DG to 
monoacylglycerol (MG). Monoacylglycerol lipase is responsible for the last non-rate limiting 
step of hydrolyzing MG to FFA and glycerol. Some of the FFA are re-esterified into new 
TG,
38
 whereas glycerol is released from the adipocyte and later taken up by the liver. The 
liver, in contrast to adipose tissue, contains glycerol kinase that converts glycerol to glycerol-
phosphate which can be used for adipogenesis or as fuel.  
1.4.2.2.1 Lipolysis regulation 
Lipolysis is strongly regulated by hormones, whereof only relatively few have an active role 
in lipolysis regulation in adults, of which the most important are catecholamines, insulin and 
atrial /brain natriuretric peptides (ANP/BNP). Thyroid stimulating hormone stimulates 
lipolysis in infants. There are a number of other hormones that stimulate lipolysis or enhance 
the lipolytic effects of catecholamines, for example growth hormone, interleukin 6, tumor 
necrosis factor α, thyroid hormones, glucocorticoids, estrogen, glucagon, parathyroid 
hormone and cholecystokinin in rodents. Insulin is the most important inhibitor of lipolysis 
but adenosine, prostaglandins, neuropeptide Y and peptide YY also have some anti lipolytic 
effects in humans. 
Catecholamines exhibit their effect in adipose tissue through four different receptors. The β1, 
β2 and β3 adrenoreceptors stimulate lipolysis via their connection to stimulatory guanine 
nucleotide binding protein that activates adenylate cyclase which leads to increased rates of 
cyclic AMP (cAMP) (Figure 3). cAMP activates protein kinase A which in turn activates 
HSL through phosphorylation. The fourth catecholamine receptor, the α2 receptor, is 
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connected to an inhibitory guanine nucleotide binding protein and decrease cAMP-levels, 
HSL activity and lipolysis. The net effect of catecholamines on lipolysis is stimulatory but the 
rate of α2- and β adrenoreceptors expressed on the cell surface determines to what extent. 
Insulin is a powerful inhibitor of lipolysis and binds to the insulin receptor. This activates the 
insulin receptor substrate which in a cascade reaction involving phosphodiesterase 3 leads to 
decreased levels of cAMP and decreased HSL activity. 
The atrial /brain natriuretric peptides (ANP/BNP) also stimulate lipolysis but by another 
pathway that leads to increased levels of cyclic guanosine monophosphate which in turn 
activates protein kinase G and HSL (Figure 3). 
 
Figure 3. 
Overview of important regulatory mechanisms of fat cell lipolysis. TG = Triglycerides, DG = Diacylglycerol MG = 
Monoacylglycerol, MGL = Monoacylglycerol lipase, FFA = Free fatty acids, HSL = Hormone sensitive lipase, HSL-P 
= Phosphorlyated HSL, ATGL= Adipose triglyceride lipase, ATP = Adenosine triphosphate, AC = Adenylate cyclase, 
cAMP = Cyclic adenosine monophosphate, PDE3 = Phosphodiesterase 3, 5´-AMP = 5´Adenosine monophosphate, 
PKA= Protein kinase A, A/B NP = Atrial /brain natriuretric peptide, A/B NPR = Atrial /brain natriuretric peptide 
receptor, GTP = Guanosine triphosphate, GC = Guanylate cyclase, cGMP = Cyclic guanosine monophosphate, PKG= 
Protein kinase G,  IR = insulin receptor, IRS = Insulin receptor substrate, Gs/Gi = guanine nucleotide binding protein 
(stimulatory/inhibitory), AR = Adreno receptor. 
1.4.2.2.2 Lipolysis in different fat depots and different metabolic conditions 
The fat cell lipolysis rate is different in different fat depots. There are also differences 
between the correlation between fat mass in different fat depots and metabolic complications. 
Changes in basal or stimulated lipolysis rate may explain some of the fat depots specific 
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correlations with metabolic disease and this has been studied extensively in different settings. 
Visceral fat cells show a higher lipolytic answer to catecholamine induced lipolysis than 
subcutaneous fat cells probably due to variations in the rate of β- and α2-adrenoreceptor 
mediated glycerol release.
40
 The anti lipolytic effects of insulin is more pronounced in 
subcutaneous than visceral adipose tissue due to differences in insulin receptor affinity.
41
   
Subcutaneous adipose tissue in the upper body has higher lipolytic response to 
catecholamines compared to lower body subcutaneous adipose tissue.
42
  
In obesity, basal lipolysis is elevated in all examined regions. Whether the antilipolytic effect 
of insulin is altered in obesity is unclear, as reviewed.
41
 The answer to stimulation of lipolysis 
seems to be different in different fat depots in obesity. One study showed that stimulated 
subcutaneous lipolysis is blunted,
37
 whereas another study showed increased stimulated 
lipolysis in visceral fat cells in obesity.
43
 
1.4.3 Adipose tissue protein production 
Over the past few decades it has become evident that adipose tissue secretes a large number 
of proteins (adipokines) that exert both local paracrine/autocrine functions as well as systemic 
endocrine effects. These adipokines are involved in different processes such as appetite 
control, inflammation, cell proliferation, adipogenesis, glucose metabolism and 
vascularization.
30
 In this thesis, mRNA levels of tumor necrosis factor α (TNFα), interleukin 
6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) were analyzed and a brief description 
of these hormones will follow below. 
1.4.3.1 Tumor necrosis factor alpha 
As the name implies macrophage derived tumor necrosis factor α was originally found to 
cause necrosis in tumor cells.
44
 Later TNFα was linked to weight loss in cancer cachexia45. In 
1993, Hotamisligil and colleagues showed that in obese rats and rats with diabetes, there was 
an increased expression of TNFα in fat cells.46 Furthermore, neutralization of TNFα lead to 
increased peripheral glucose uptake in response to insulin.
46
 Increased levels of TNFα has 
also been found in obese humans with hyperinsulinemia.
47
 Subsequent investigations have 
shown that most of the TNFα production in adipose tissue is not derived from adipocytes but 
from infiltrating macrophages.
48
 The TNFα from adipose tissue is not released into the 
circulation but instead exerts multiple para/autocrine effects in adipose tissue, as reviewed.
48
 
These functions include impairing insulin action by decreased expression of glucose 
transporters, down regulation of IRS function and expression. TNFα also stimulates lipolysis 
by effects on HSL and perilipin. Perilipin is a protein involved in storage of lipids in lipid 
droplets inside the adipocyte. TNFα release from adipocytes correlates negatively with 
insulin induced lipogenesis in human adipose tissue.
49
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1.4.3.2 Interleukin 6 
Interleukin 6 is a pro-inflammatory cytokine produced by both adipocytes and stroma 
vascular fraction cells in adipose tissue. It correlates positively with adiposity and weight 
reduction leads to reduced levels of IL-6 as well as improved insulin sensitivity.
30, 50
 IL-6 
induces an increase of C-reactive protein, a marker of inflammation. Both C-reactive protein 
and IL-6 are associated with development of type 2 diabetes.
51
 Induced hyperinsulinemia 
increases levels of plasma IL-6 which may be a mechanism that could contribute to the low-
grade inflammation seen in obesity.
52
 IL-6 is also produced in skeletal muscle during exercise 
and a recent review suggest that, in contrast to adipose tissue derived IL-6,  IL-6 from the 
muscle actually have beneficial effects on metabolism by increasing insulin sensitivity, 
partially through increasing levels of GLP-1.
53
 
1.4.3.3 Monocyte chemoattractant protein 1 
Monocyte chemoattractant protein 1 (MCP-1), also called chemokine ligand 2 (CCL-2) 
increases in obesity and type 2 diabetes and the expression of MCP-1 is increased in omental 
compared to subcutaneous adipose tissue, as reviewed.
54
 MCP-1 contributes to macrophage 
accumulation in adipose tissue. Obese homozygous MCP-1 knockout mice exhibit reduced 
insulin resistance and reduced hepatic steatosis.
55
 Acute administration of MCP-1in 
circulating blood leads to insulin resistance but not macrophage infiltration into adipose tissue 
in rats, whereas an infusion of MCP-1 over a long time also results in macrophage infiltration 
in adipose tissue.
56
 This indicates that MCP-1 might have other effects on insulin resistance 
irrespective of macrophage infiltration and inflammation. Endothelial cells from human 
subjects with diabetes that were treated with high levels of glucose resulted in 40-70% 
increased release of MCP-1 which may be a partial explanation how hyperglycemia leads to 
increased inflammation.
57
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2 AIMS 
Obesity and visceral fat accumulation are strong risk factors for the development of type 2 
diabetes and cardiovascular disease. Other factors than fat accumulation per se are also 
important for the development of obesity related complications. This thesis aims to study 
depot specific properties of fat cell size and lipolysis in relation to cardiovascular risk factors. 
In addition, the aim was to evaluate the potential metabolic effects of removing a large 
portion of visceral adipose tissue.  
2.1 STUDY-SPECIFIC AIMS 
I. To investigate whether fat cell size is differently linked to the metabolic 
phenotype in subcutaneous and visceral adipose tissue. A second aim of this 
study was to elucidate whether co-existing subcutaneous and visceral 
hyperplasia, compared to hypertrophy, correlates with a more benign 
metabolic phenotype. 
 
II. To investigate whether changes in subcutaneous fat cell volume correlates 
more strongly than fat mass changes with improvements in insulin resistance 
following weight reduction. 
 
III. To investigate whether lipolysis in subcutaneous and visceral adipocytes 
display depot specific correlations with cardiovascular risk factors and the 
metabolic syndrome.  
 
IV. To investigate whether removal of the greater omentum in conjunction with 
gastric bypass operation results in enhanced improvement of insulin 
sensitivity and cardiovascular risk factors compared to gastric bypass 
operation alone.  
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3 MATERIAL AND METHODS  
3.1 SUBJECTS 
The subjects in this thesis were recruited from four different surgical centers in Stockholm 
(Ersta Hospital, Karolinska University Hospital Huddinge, Södertälje Hospital and 
Danderyds Hospital) after they had been accepted for gastric bypass operation. To be eligible 
for inclusion, the subjects had to be female, between 18-70 years old and have a BMI ≥ 40 
kg/m
2
. Subjects could also be included with a BMI ≥ 35 kg/m2 if they had concomitant 
obesity associated complications such as type 2 diabetes or hypertension. Exclusion criteria 
were treatment with warfarin, insulin or severe ongoing psychiatric disease. All subjects were 
part of a randomized clinical trial (study IV) and were randomized to either gastric bypass 
operation alone or gastric bypass operation in conjunction with omentectomy. They were re-
investigated two years postoperatively. Figure 4 shows a flowchart for inclusion and 
exclusion of patients to study IV.  
 
Figure 4. 
Flow chart of included subjects in Study IV.  
The number of subjects included in each study is presented in Table 1. Study I and III were 
cross-sectional studies and analyzed data that had been collected pre-operatively. Study II and 
IV were longitudinal studies with data both from preoperative examinations and from a 
follow up examination two years post-operatively when the subjects had been weight stable 
for at least three months. Sixty-two subjects were reexamined post-operatively. The clinical 
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characteristics of the subjects are presented in Table 2. In study II an additional 62 healthy 
subjects with a large inter-individual variation in body mass index (20-62 kg/m
2
) were 
included to obtain a reliable relationship between fat mass and fat cell volume. 
Table 1. 
Number of subjects included in each study and reason for exclusion. 
 Before 
surgery 
After 
surgery 
Comments 
Study I 80  One subject excluded due to missing data 
on both subcutaneous and visceral fat cell 
size. 
Study II 62 62 Only subjects that had participated in both 
pre- and post-operative examinations were 
included. In addition, 62 healthy women 
with a large inter-individual variation in 
BMI were included to obtain a standard 
curve for adipose tissue morphology.  
Study III 73  Seven patients were excluded since they 
had a fasting plasma glucose ≥ 7.0 mmol/l. 
One subject excluded due to missing data 
on both subcutaneous and visceral fat cell 
lipolysis. 
Study IV 81 62  
 
3.2 RANDOMIZATION 
Randomization was performed in blocks of 20 patients. At the beginning of the gastric bypass 
operation, an opaque envelope was opened that contained information of allocation to gastric 
bypass operation alone (non-omentectomy group) or gastric bypass plus omentectomy 
(omentectomy group). Researchers that participated in collection of data and subjects were 
blinded to group allocation. 
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Table 2. 
Clinical characteristics of the cohort. Values are mean ± SD. 
 Before surgery After surgery 
Age (years) 42±9 45±9 
Body mass index (kg/m
2
) 44±5 29±4 
Waist circumference (cm) 132±11 97±12 
Total body fat (kg) 62±11 30±11 
Estimated visceral adipose tissue in the android region (kg) 2.4±0.8 0.7±0.4 
Estimated subcutaneous adipose tissue in the android region (kg) 4.0±1.0 1.8±0.9 
Plasma glucose (mmol/l) 5.5±1.2 4.9±0.6 
Plasma insulin (mU/l) 16.5±8.6 4.8±1.9 
HOMA-IR (mmol/l x mU/l) 4.1±2.5 1.0±0.4 
Glucose disposal rate (mg glucose/kg body weight/min) 3.8±1.4 6.6±1.5 
 
3.3 ETHICAL CONSIDERATIONS 
The studies were performed in accordance with the ethical standards of the Declaration of 
Helsinki and approved by the local ethics committee in Stockholm. Signed informed consent 
was obtained from all subjects prior to inclusion. 
3.4 CLINICAL EXAMINATIONS AND PROCEDURES 
 
Patients were examined at the laboratory up to three weeks before operation. At that time, 
body weight had been stable for at least six months. The subjects came to the laboratory after 
an overnight fast. Weight was measured with a digital scale (TANITA TBF-305) to the 
nearest 0.5 kg. Waist circumference was measured (at the midpoint between the iliac crest 
and the lowest rib with a non-stretchable tape measure) and height was measured to the 
nearest 0.5 cm. Blood pressure was measured in the right arm with a cuff of the appropriate 
size with a fully automatic device (Omron M10-IT, Omron Health Care, Hoofddorp, The 
Netherlands). Blood samples were taken for subsequent analyses of fasting insulin, glucose, 
cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides, FFA, apolipoprotein 
A1 (Apo A1), apolipoprotein B (apo B), TNF-α, C-reactive protein, fibrinogen, MCP-1 and  
 14 
 
IL-6. Low density lipoprotein (LDL) cholesterol was estimated with the Friedewald formula 
as follows
58
 
LDL cholesterol = Cholesterol –  High density cholesterol –  0,45 x Triglycerides  
HOMA-IR was calculated from the formula developed by Matthews and used to evaluate 
hepatic insulin resistance.
29
 
 HOMA-IR = fasting blood glucose (mmol/l) x fasting plasma insulin (mU/l) / 22.5. 
The subjects were instructed to live their life as usual after their visit to the laboratory and 
were not put on low-calorie diet prior to the operation. The body weight was essentially the 
same at the time of baseline examination at the laboratory and at the time of operation.  
Approximately 24 months post-surgery, when then subjects had been weight-stable for at 
least 3 months, thy were reexamined according to the same protocol mentioned above. 
3.4.1 Definition of the metabolic syndrome 
The guidelines from the International Diabetes Federation was used for definition of the 
metabolic syndrome, i.e. waist circumference ≥ 80 cm plus any 2 of the following; Systolic 
blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg, raised fasting plasma 
triglycerides > 1.7 mmol/l, fasting HDL cholesterol < 1.29 mmol/l or raised fasting plasma 
glucose ≥ 5.6 mmol/l.9  
3.4.2 Measurement of body composition by Dual-energy x-ray 
absorptiometry  
Body composition (total-, android-, gynoid fat mass and android/gynoid fat ratio) was 
measured with dual-energy x-ray absorptiometry (DEXA) using a GE-Lunar iDXA with the 
software enCORE (version 14.10.022) from GE Healthcare, Madison, WI, USA.
59
 In 
addition, using the CoreScan feature, the software estimated the amount of subcutaneous 
adipose tissue in the android region (ESAT) and then calculated the amount of visceral 
adipose tissue in the android region (EVAT). Figure 5 shows a schematic view of 
measurement of fat mass in the android region (defined inferiorly at the pelvis cut line, 
superiorly by 20% of the distance between neck cut and the pelvis, laterally at the arm cut 
lines) and the software estimation of ESAT. The following formula is used in the CoreScan 
feature: EVAT = total body fat in the android region – ESAT. Estimated EVAT using the 
formula shows a very high concordance (r
2
=0.96) with measurement of visceral adipose 
tissue using computed tomography, which is the gold standard method.
60
 Since both android 
fat mass and EVAT are valid measures ESAT could be calculated as total android fat minus 
EVAT. 
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Figure 5.  
Dual-energy x-ray absorptiometry used to measure android and gynoid fat mass (left) and estimation of 
subcutantoues adipose tissue (ESAT) that is used to estimate visceral adipose tissue (EVAT) (right). 
3.4.3 Hyperinsulinemic euglycemic clamp 
We used hyperinsulinemic euglycemic clamp to measure whole body insulin sensitivity in 
vivo. Two catheters were inserted, one into a forearm vein for infusions and a second catheter 
into a vein on the dorsal side of the hand used for blood sampling. To obtain arterialised 
blood, the hand was kept in a heating box (Figure 6, MTA, Karolinska University Hospital, 
Stockholm, Sweden) with a temperature of 63ºC during the clamp.
61
 All infusions during the 
clamp were given in the forearm vein. Body area was calculated from a formula developed by 
Du Bois.
62
 At the beginning of the clamp a bolus dose of insulin (1.6 U/m
2
 body surface area; 
Actrapid, Novo Nordisk, Copenhagen, Denmark) was given. The bolus injection was 
followed by a continuous infusion of insulin (0.12 U/m
2
 body surface area/minute) suspended 
in 82 ml sodium chloride (9 mg/ml) together with 2 ml (200 g/l) human albumin (1.7 
mg/minute Albunorm, Octapharma, Stockholm, Sweden) and 16 ml potassium cloride (67 
µmol/minute) with an infusion rate of 25 ml/h for 120 minutes (Figure 6). Blood glucose was 
ESAT inner wall 
ESAT outer wall 
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measured in duplicates every fifth minute (Hemocue, Ängelholm, Sweden) and euglycemia 
(4.5 to 5.5 mmol/l) was maintained through a variable intravenous infusion of glucose (200 
mg/ml). The last sixty minutes of the clamp was considered to be steady state and the 
infusion rate of glucose during that time period was used for calculation of whole-body 
insulin sensitivity (expressed as glucose disposal rate with the unit mg glucose/kg body 
weight/minute). Ninety-five percent of the blood glucose values during the last sixty minutes 
of the clamp were within euglycemic level. The average blood glucose levels during steady 
state were 5.05±0.19 mmol/l at baseline and 5.10±0.18 mmol/l at follow up. The average 
insulin levels at steady state during clamp were 243±77 mU/l at baseline and 169±42 mU/l at 
follow up.  
 
 
 
Figure 6. 
Hyperinsulinemic euglycemic clamp and the heating box used to obtain arterialized blood. 
3.4.4 Gastric bypass operation and omentectomy 
In the past decade, bariatric surgery has become a common method to treat obesity and Roux 
en Y gastric bypass operation is the most prevalent method. Nowadays, almost all RYGB are 
performed with laparoscopic technique, but at the time this study was performed, both open 
and laparoscopic techniques were used in clinical practice. Open surgery was needed in order 
to remove the entire major omentum. As study IV was a double blinded study, all subjects 
underwent open surgery. An upper midline incision was made and a small gastric pouch (20-
30 ml) was created with the help of linear staples. Linear or circular staples were used for 
gastro-enteroanastomosis and linear staples were used for creation of the entero-
enteroanastomosis. The alimentary limb was approximately 120 cm and the bilio-pancreatic 
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limb about 75 cm, respectively. In subjects allocated to omentectomy, the entire major 
omentum was resected. 
3.5 FAT CELL EXAMINATIONS  
3.5.1 Adipose tissue biopsies 
 
A subcutaneous injection of 25 ml lidocaine 10 mg/ml (without adrenalin), approximately 15-
30 cm laterally of the umbilicus, was used for local anesthesia. Under sterile conditions a 
small incision was made to help the aspiration needle to penetrate the skin. Using a syringe 
with negative pressure generated by a 10 ml syringe, subcutaneous fat was aspirated and 
subsequently rinsed in sodium chloride over a plastic filter (Sefar Nitex 06-210/33, Bigman 
AB, Sweden) (Figure 7). Coagulated blood was manually removed with the help of a spatula. 
At the beginning of surgery, a visceral fat biopsy from the greater omentum was obtained and 
then handled in the same way as the subcutaneous fat biopsy. 
 
Figure 7.  
Abdominal subcutaneous fat biopsy and aspirated adipose tissue.     
3.5.2 Isolation of fat cells and determination of fat cell size and number 
The fat biopsies were transported in sodium chloride to the lipid laboratory where they were 
once again rinsed with sodium chloride over a plastic filter (Sefar Nitex 06-210/33, Bigman 
AB, Sweden). The fat was washed several times with a washing buffer (Krebs Ringer 
Phosphate buffer with 1% bovine serum albumin) and subsequently incubated in 37ºC water 
bath under gentle shaking in a washing buffer with 0.5 mg/ml collagenase and 4% bovine 
serum albumin for 60 minutes. The adipocytes were then washed again (Krebs Ringer 
Phosphate buffer with 0.1% bovine serum albumin) and filtered thrice through a nylon filter.  
 A droplet of cell suspension was placed on a microscope slide and covered with a cover-
slide. The diameter of 100 cells was determined manually using a ruler fitted in the ocular of 
the microscope (unpublished data from our laboratory shows no difference in average 
diameter whether 100 or 300 cells are measured). With the formula described below, the 
diameter of the fat cells was used to calculate fat cell volume. 
 18 
 
 
 
𝑉 =  (
𝜋 ∙ 𝑑3
6
) (µm3) 
V = cell volume d = diameter (µm) 
Although the diameter of fat cells is normally distributed, its cube is skewed and as 
previously discussed,
31, 63
 the arithmetic mean of d
3
 cannot be used to calculate mean fat cell 
volume. Instead the average fat cell volume is approximated by a computer program using 
the formula 
Vmean = [
𝜋
6
] X [3𝜎2 × 𝑑 + 𝑑
 3
] 
where 𝑑 is the mean diameter and σ is the standard deviation of the diameter. 
The average density of triolein (triglycerides) is 0.915 g/cm
3
 and this was multiplied with the 
fat cell volume to obtain mean fat cell weight. The fat mass was then divided by the mean fat 
cell weight to get fat cell number (total or in different depots).   
3.5.3 Determination of fat cell morphology 
Previous publications from our research group have shown that the relationship between fat 
cell volume and fat mass is curve-linear.
34, 35
 The relationship can be described with the 
following formula 
𝑉 =
(𝑎 ∙ 𝑚)
(1 + 𝑏 ∙ 𝑚)
 
where V =  mean cell volume (pl) and m = fat mass (kg). The variables a (pl/kg) and b (pl/kg) 
are obtained by fitting the formula to subject data. The difference between the actual 
measured fat cell volume and the expected fat cell volume from the mean curve fit is an 
indication of the adipose morphology. A positive value indicates hypertrophy, whereas a 
negative value is indicative of hyperplasia (example in Figure 8). In study I the morphology 
was determined both with variables a and b from previous publications.
34, 35
 Total fat mass 
assessed with DEXA was used in study I. Separate curves were used for abdominal 
subcutaneous and visceral adipose tissue as fat cell size is different in the two compartments. 
In study II, new standard curves were created for subjects before and after weight reduction 
and estimated subcutaneous adipose tissue was used as a measure of fat mass. 
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Figure 8. 
Determination of adipose tissue morphology value. A fat cell volume that is larger than expected fat cell volume from 
the cure fit model (hypertrophy) renders a positive morphology value whereas a small mean fat cell volume below the 
curve fit model (hyperplasia) gives a negative morphology value.34  
3.5.4 Lipolysis experiments 
Isolated fat cells that were diluted in Krebs-Ringer phosphate buffer (pH 7.4) with bovine 
serum albumin (20 mg/ml), glucose (1 mg/ml) and ascorbic acid (0,1 mg/ml) were incubated 
in duplicate with different concentrations of noradrenaline (10
-12
 to 10
-4
  mol/l) for 2 hours in 
a shaking bath at 37ºC. Noradrenaline, a non-selective α- and β-adreno receptor agonist, was 
the lipolytic agent of choice since it is an important endogenous agent. After incubation the 
samples were put on ice to stop lipolysis. A fat cell free aliquot was removed and used for 
measurement of glycerol release with a very sensitive bioluminescent method as described by 
Hellmer and colleagues.
64
 As mentioned before, during lipolysis, each triglyceride molecule 
is broken down into three fatty acids and one glycerol molecule. Fat cells do not contain 
glycerol kinase and therefore are unable to reuse glycerol, making glycerol a good marker for 
lipolysis. The luminometer measures light emitted in the following reactions 
𝐴𝑇𝑃 + 𝑔𝑙𝑦𝑐𝑒𝑟𝑜𝑙 
𝐺𝑙𝑦𝑐𝑒𝑟𝑜𝑘𝑖𝑛𝑎𝑠𝑒
→           𝑔𝑙𝑦𝑐𝑒𝑟𝑜𝑙 − 1 − 𝑝ℎ𝑜𝑠𝑝ℎ𝑎𝑡𝑒 + 𝐴𝐷𝑃 
𝐴𝑇𝑃 + 𝑙𝑢𝑐𝑖𝑓𝑒𝑟𝑖𝑛 + 𝑂2  
𝐿𝑢𝑐𝑖𝑓𝑒𝑟𝑎𝑠𝑒
→        𝑂𝑥𝑦𝑙𝑢𝑐𝑖𝑓𝑒𝑟𝑖𝑛 + 𝐴𝑀𝑃 + 𝑃𝑃𝑖 + 𝐶𝑂2 + 𝑙𝑖𝑔ℎ𝑡 
Luciferase and glycerokinase compete for the use of ATP and a decreased light indicates 
higher lipolytic activity. The glycerol concentration was calculated with a computer program. 
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4 RESULTS 
All results included in this thesis are presented and discussed in detail in each individual 
article. A summary of the most important findings will be presented below. 
4.1 REGIONAL IMPACT OF ADIPOSE TISSUE MORPHOLOGY ON THE 
METABOLIC PROFILE IN MORBID OBESITY (STUDY I) 
Study I aimed to investigate whether fat cell size is linked to metabolic and inflammatory 
markers differently in subcutaneous and visceral adipose tissue in obese women. Fat cell 
volume (FCV) in the subcutaneous depot (FCV= 989±174 pl) were larger as compared to the 
average visceral fat cell volume (FCV= 631±184 pl; p< 0.0001). As expected, subcutaneous 
fat cell size correlated significantly with insulin sensitivity measured by hyperinsulinemic 
euglycemic clamp (r= -0.40 p= 0.004 Figure 9), fasting insulin (p= 0.0001) and fasting 
glucose (p= 0.0009). Visceral fat cell size also had an inverse relationship to insulin 
sensitivity (r= -0.29 p= 0.01 Figure 9) but not as strongly as subcutaneous fat cell size. There 
was also a positive correlation between visceral fat cell size and TG, cholesterol (Figure 9) 
and LDL cholesterol (r= 0.32-0.38 p= 0.0006-0.003). Fat cell size in neither the subcutaneous 
nor the visceral fat depot correlated significantly with mRNA levels of TNFα, MCP-1 or IL-6 
in subcutaneous or visceral adipose tissue (p= 0.21-0.70). In multiple regression analysis with 
subcutaneous and visceral fat cell size as independent variables, subcutaneous fat cell volume 
related significantly with insulin, glucose and glucose disposal rate (p= 0.002-0.005). On the 
other hand, visceral fat cell volume correlated with plasma cholesterol, LDL cholesterol, TG 
and apo B (p= 0.002-0.015). This indicates that fat cell volume has depot specific impact on 
metabolic parameters, where large subcutaneous fat cells correlate with insulin resistance and 
large visceral fat cells correlate with dyslipidemia.   
Study I also aimed to investigate whether hyperplasia in both visceral and subcutaneous 
regions correlated with a more benign metabolic profile than hypertrophy in both regions. 
There were no significant differences between the combined hyperplasia and combined 
hypertrophy group regarding, age, BMI, waist circumference or body fat percent. On the 
other hand, significant and potentially clinically relevant differences were seen between the 
combined hyperplasia and combined hypertrophy subjects when looking at glucose disposal 
during clamp (4.8 and 3.3 mg glucose / kg body weight/ min respectively), HOMA-IR (2.2 
and 5.3 mmol/l x mU/l respectively), cholesterol (4.4 and 5.1 mmol/l respectively), LDL (3.0 
and 3.7 mmol/l respectively) and TG (1.2 and 1.9 respectively) (p= <0.0001-0.02).  
The finding that combined adipose hyperplasia, in comparison to combined hypertrophy, 
correlates with insulin sensitivity and a more beneficial lipid profile may have important 
clinical impact because it puts adipose morphology phenotype, independently of adipose 
mass, as an important metabolic regulator.  
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Figure 9.  
Subcutaneous fat cell volume (left) and visceral fat cell volume (right) and its correlation to glucose disposal rate 
measured by hyperinsulinemic euglycemic clamp (top), triglycerides (middle) and cholesterol (bottom).   
4.2 CHANGES IN SUBCUTANEOUS FAT CELL VOLUME AND INSULIN 
SENSITIVITY AFTER WEIGHT LOSS (STUDY II) 
After our findings in study I, we were eager to further analyze the clinical impact of fat cell 
size. In study II we investigated whether changes in subcutaneous fat cell volume in response 
to bariatric surgery correlate with improvements in metabolic risk factor profile following 
weight reduction. The 62 subjects who had undergone both the baseline and a follow-up 
examination two years post-operatively were included in the study. Noteworthy, the cohort 
consisted of subjects who had undergone either regular RYGB (n=29) or RYGB in 
conjunction with omentectomy (n=33) (Figure 3). However, there were no significant clinical 
differences in the results between these groups (data not shown). As expected, all measured 
clinical parameters improved following RYGB and subsequent weight reduction (p< 0.0001 
for all measured variables). Subcutaneous fat cell size decreased (p< 0.0001) but 
subcutaneous fat cell number was not statistically different following weight reduction (p= 
0.39) which is in concordance with previous studies.
34, 65
   
The most important result in study II was that changes in insulin sensitivity (measured by 
hyperinsulinemic euglycemic clamp) correlated with changes in subcutaneous fat cell size 
(ρ= 0.38 p= 0.0057) but not changes in estimated subcutaneous fat mass (ρ= 0.11 p= 0.31) or 
changes in total fat mass (ρ= 0.26 p= 0.06). This was further analyzed with multiple 
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regression with changes in insulin sensitivity as dependent variable and changes in 
subcutaneous fat cell size as one independent variable (r= 0.32 p= 0.04 and r= 0.33 p= 0.07 
respectively) and changes in subcutaneous (p=0.99) or total fat mass (p=0.85)  as an 
additional independent variable. Changes in subcutaneous fat cell size seems to correlate 
much stronger with changes in whole body insulin sensitivity than changes in fat mass even 
though the correlation was only of borderline significance when corrected for changes in total 
fat mass.  
4.3 VISCERAL FAT CELL LIPOLYSIS AND CARDIOVASCULAR RISK 
FACTORS IN OBESITY (STUDY III) 
Study III was designed as a cross-sectional study that investigated whether lipolysis in 
subcutaneous and visceral adipocytes display depot specific correlations with cardiovascular 
risk factors in obesity. The study included 73 obese women (seven women from the cohort in 
study IV had been excluded due to fasting plasma glucose > 7.0 mmol/l and one subject due 
to missing data on both subcutaneous and visceral fat cell lipolysis). The correlation between 
noradrenaline stimulated maximal lipolysis and clinical parameters was determined with 
simple regression analysis. There was a significant correlation between visceral fat cell 
lipolysis and plasma insulin, HOMA-IR, glucose disposal rate, cholesterol, LDL cholesterol, 
TG, and apo B (r= 0.28-0.44 p= 0.0001-0.02). However, visceral fat cell lipolysis did not 
correlate with fasting glucose, HDL cholesterol or apo A1 (r=0.02-0.16 p= 0.18-0.90). The 
positive correlations remained significant after adjustment for total body fat %, abdominal- or 
hip body fat percent by multiple regression analysis. In contrast, there were no significant 
relations between maximal subcutaneous fat cell lipolysis and any of the above mentioned 
parameters (r= 0.001-0.23 p= 0.055-0.99). To further illustrate the impact of depot specific 
adipocyte lipolysis, subjects were divided into quartiles depending on their lipolysis rate. 
Clinical parameters in the quartiles with the highest and lowest lipolysis rate were then 
compared. As expected, no significant differences in clinical parameters were seen between 
the lowest and highest quartile of lipolysis in subcutaneous fat cells. There were no 
significant differences in anthropometric measurements between the highest and lowest 
quartile of visceral fat cell lipolysis (p= 0.50-0.99). On the other hand, subjects in the highest 
quartile of visceral fat cell lipolysis had, compared to the quartile with the lowest visceral fat 
cell lipolysis rate, a more unfavorable metabolic profile. For example, plasma insulin  was 
22.4 mU/l compared to 11.4 mU/l (p= 0.0004), plasma glucose was 5.54 mmol/l compared to 
5.16 mmol/l (p=0.03), glucose disposal rate 3.23 mg/glucose/kg/min compared to 4.45 mg 
glucose/kg/min (p= 0.0098), cholesterol 5.32 mmol/l compared to 4.68 mmol/l (p=0.016) and 
TG 1.93 mmol/l compared to 1.25 mmol/l (p= 0.003).  
We subsequently divided the subjects, based on whether they fulfilled the criteria for the 
metabolic syndrome according to the International Diabetes Federation as described,
9
 and 
then analyzed the differences in adipocyte lipolysis between subjects with or without the 
metabolic syndrome. Subjects with the metabolic syndrome had a 40% higher visceral fat cell 
 23 
 
lipolysis rate than subjects without the metabolic syndrome. No differences were seen in 
subcutaneous maximal fat cell lipolysis rate.  
To conclude, visceral, as opposed to subcutaneous, fat cell lipolysis rate correlates with 
insulin resistance, dyslipidemia and hypertension. Subjects with the metabolic syndrome have 
higher visceral fat cell lipolysis rate than subjects without the metabolic syndrome.  
4.4 OMENTECTOMY IN ADDITION TO GASTRIC BYPASS SURGERY AND 
INFLUENCE ON INSULIN SENSITIVITY: A RANDOMIZED DOUBLE BLIND 
CONTROLLED TRIAL (STUDY IV) 
Of 81 included subjects, 62 were reexamined two years post-surgery and a flowchart for the 
study subjects is presented in Figure 4. At baseline, the non-omentectomy and omentectomy 
group were very similar in all measured parameters such as weight, age, BMI, body fat 
percent, blood lipids and insulin sensitivity measured by both HOMA-IR and 
hyperinsulinemic euglycemic clamp. The average weight of the removed omentum was 552 ± 
227g. As expected, there was a substantial reduction of mean body weight from 117 kg to 79 
kg following RYGB (Figure 10 and Figure 11) and all measured parameters improved 
significantly. 
 
 
 
Figur 10. 
Example of weight reduction following gastric bypass operation, before operation (left) and after operation (right). 
The bandaid indicates the location of the subcutaneous fat biopsy.  
 
However, there was no difference between the groups in the primary outcome measure, 
insulin sensitivity measured by hyperinsulinemic euglycemic clamp, either at baseline (3.9 ± 
1.2 to 6.7 ±1.6 mg glucose/kg body weight/minute in the non-omentectomy group vs. 3.6 ± 
2.6 to 6.6 ± 1.5 mg glucose /kg body weight/minute in the omentectomy group), follow up 
(6.7 ± 1.6  mg glucose/kg body weight/ min in the non-omentectomy group vs. 6.6 ± 1.5 mg 
glucose/kg body weight/min in the omentectomy group).  
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In fact, no statistically significant differences between improvement in any measured 
parameters were seen when comparing the non-omentectomy and omentectomy group       
(p= 0.17-0.98), besides a lower reduction of triglycerides in the omentectomy group (TG 1.5 
to 0.8 mmol/l in the non-omentectomy group and 1.5 to 1.0 mmol/l in the omentectomy 
group p = 0.019). We considered the differences of reduction of TG a random finding which 
did not remain significant after a Bonferroni p-value correction. 
 
 
Figure 11.  
Weight development following gastric bypass operation. 
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5 DISCUSSION 
In the following chapter, a general discussion about the most important findings in the 
studies, along with some methodological considerations, will be presented.  
It has been known for several decades that enlarged subcutaneous fat cells are associated with 
hyperinsulinemia,
32
 and as expected, study I confirmed that large subcutaneous fat cell size 
correlated with both fasting hyperinsulinemia and decreased glucose disposal rate (more 
strongly than visceral fat cell size). On the other hand, visceral fat cell size, as opposed to 
subcutaneous fat cell size, correlated with dyslipidemia. This suggests that fat cell size has 
depot specific effects on the cardiovascular risk factor profile. Furthermore, study I showed 
that combined hyperplasia in both the subcutaneous and visceral adipose depot, compared to 
combined hypertrophy, was related to a healthier metabolic profile with higher insulin 
sensitivity and lower plasma lipid levels. Thus, fat cell cellularity has an impact on the 
metabolic risk factor profile. This has later been confirmed in a study on monozygotic twins 
with dis- concordant body weight where subjects with hyperplastic obesity (hyperplasia was 
defined as more fat cells in the obese than lean twin) had a more benign metabolic profile 
compared to subjects with hypertrophic obesity (hypertrophy defined as less fat cells than 
lean twin).
66
  
Study II found that reduction of subcutaneous fat cell size actually correlates stronger than 
reduction of subcutaneous fat mass with improved in insulin sensitivity following weight 
reduction. The results from study I and study II suggest that subcutaneous fat cell size, 
independently of fat mass, is an important intrinsic property of subcutaneous adipose tissue 
that correlates with insulin resistance. The underlying mechanisms behind the impact of fat 
cell size on the metabolic profile are still unknown but some potential explanations will be 
discussed below.  
Increasing obesity (which also leads to increased fat cell size), shifts the adipokine secretion 
pattern towards a pro-inflammatory profile.
30
 Macrophages in adipose tissue change their 
expression of surface markers towards a more pro-inflammatory pattern (from M2 to M1- 
expression of macrophages) which results in insulin resistance, as reviewed.
30
 On the other 
hand, in study I, we did not see any correlation between fat cell size and mRNA levels of 
inflammatory markers such as TNF-α, MCP-1 and IL-6, suggesting a less important role of 
fat cell size for inflammation in obesity. However, in lean subjects our group has observed a 
linear relationship between TNF-α levels, and cellularity levels, with subjects with 
hyperplastic adipose tissue having lower TNF-α levels than subjects with hypertrophic 
adipose tissue.
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In addition to this, enlargement of adipocytes can, at least in mice, lead to impaired 
angiogenesis and hypoxia.
67
 Hypoxia has in turn been found to alter adipokine secretion and 
reduce insulin sensitivity, as reviewed.
68
 If we further speculate, adipocyte turnover and 
remodeling of adipose tissue might play a role how fat cell size changes have an impact on 
insulin sensitivity. Adipocyte turnover during the study period of two years is approximately 
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20%.
34
 In study II, we saw that the curve of mean fat cell volume and subcutaneous adipose 
tissue differed significantly before and after weight reduction (p= 0.03). The new adipocytes, 
developed during a period of caloric restriction and weight reduction, may have different size 
and properties than the adipocytes they replace, resulting in improvement of the metabolic 
profile.    
Study III investigated adipocyte lipolysis rate in different depots and found that visceral fat 
cell lipolysis rate, in contrast to subcutaneous fat cell lipolysis rate, correlated with 
cardiovascular risk factors. In subjects with the metabolic syndrome visceral, but not 
subcutaneous fat cell lipolysis, was elevated by 40% compared to subjects not fulfilling the 
criteria for the metabolic syndrome. These results highlight visceral fat cell lipolysis as a 
possible partial explanation why visceral fat accumulation is associated with cardiovascular 
risk factors. The potential effect of enhanced FFA release from visceral adipose tissue to the 
liver is further mentioned below in the discussion about differences between HOMA-IR and 
hyperinsulinemic euglycemic clamp.  
Study IV aimed to investigate the potential additional positive effects of removing the greater 
omentum in conjunction with RYGB compared to RYGB alone. When study IV was planned 
in 2003, only one pilot study had previously been published that investigated the potential 
positive effects of omentectomy (in conjunction with gastric banding, a kind of bariatric 
surgery that is no longer widely used).
69
 The previous study showed a potential enhanced 
improvement in oral glucose tolerance and increased weight reduction in the subjects who 
had undergone omentectomy. Therefore a larger randomized controlled trial was planned to 
determine if omentectomy in conjunction with gastric bypass surgery really had additional 
positive effects. Due to various reasons, the study did not start until 2006 and ended in 2011. 
During that time, other groups had already performed and published several clinical trials 
studying omentectomy in conjunction with RYGB.
70-75
 Therefore, the novelty of the present 
study was not very high when it was published. Nevertheless, our study was larger than the 
earlier ones, had a fairly long follow up time, and used the gold standard method to determine 
insulin sensitivity which gave it some impact. The short-term studies with a follow-up of only 
1-3 months showed some inconsistencies regarding the potential effect of omentectomy. 
Hepatic but not peripheral insulin sensitivity was improved by omentectomy one month post-
operatively in one study.
71
 Another short-term study concluded that omentectomy added to 
favorable changes in glucose homeostasis although the improvement was only significant 
within the omentectomy group and not significantly different from the control group.
72
 On 
the other hand, a third short-term study with a follow up of 1-3 months post-operatively did 
not see any effect of omentectomy.
73
 Furthermore, four studies with relatively long follow-up 
periods of 12-24 months did not find any enhanced improvement of insulin sensitivity 
following gastric bypass in conjunction with omentectomy.
70, 74-76
  
The results in study IV concur with results from the other published studies, with a follow up 
time of at least one year,
70-75
 that removal of the greater omentum in conjunction with RYGB 
does not have any additional beneficiary effects on insulin sensitivity or weight reduction.  
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The weight of the removed omentum is only about 2% of the total weight reduction achieved 
by RYGB. Thus, it is possible that the positive effects of omentectomy are clouded by the 
massive overall weight reduction. However, Fabbrini and colleagues studied 7 obese subjects 
with type 2 diabetes who underwent isolated omentectomy and they did not see any 
improvement in insulin sensitivity after 3 months.
70
  
Interestingly, Klein and colleagues investigated surgical removal of abdominal subcutaneous 
adipose tissue by liposuction and did not see any effect on fat cell size or improvement of 
insulin sensitivity or the lipid profile either at 3 months
77
 or 4 years post-surgery.
78
 These 
results suggest that positive metabolic effects of weight reduction are likely closely associated 
with a different caloric input/output and/or a change in fat cell size rather than the weight loss 
per se. Most subjects that have undergone substantial weight reduction will eventually regain 
some weight and effects on the metabolic profile as well as fat cell size would of course be 
very interesting to study.  
Adipose tissue may also have positive effects by acting as a “buffer” for the influx of dietary 
fat and prevent ectopic lipid storage in liver and muscle which have been shown to lead to 
impaired insulin signaling, as reviewed.
79
 Obese and lean subjects have approximately the 
same plasma levels of FFA, while TG, insulin and glucose levels are higher in obese 
subjects.
80
 Subcutaneous adipose tissue in obese compared to lean is characterized by a 
decreased uptake,
80
 and lipolysis followed by oxidation is also decreased.
81
 It has been 
suggested that a high storage but low triglyceride removal promotes fat tissue accumulation 
whereas reduced triglyceride storage capacity and TG removal promotes dyslipidemia.
81
 
Surgical removal of visceral or subcutaneous adipose tissue may result in even more 
decreased capacity in the obese subjects to store and mobilize FFA which could lead to 
increased levels of FFA and ectopic fat storage. In addition, subjects that undergo surgical 
removal of adipose tissue do not necessarily change their food intake and may continue to 
have the same habits that once led to their obesity. This may also contribute to the persistent 
metabolic profile despite a decrease in body fat mass.  
5.1 STRENGTHS AND LIMITATIONS 
5.1.1 Study design 
The different study designs in this thesis (study I and III are cross sectional observational 
studies, study II a longitudinal cohort study and study IV a randomized double blind 
controlled trial) have an impact on what conclusions can be made from each study. Cross-
sectional observational studies have a relatively lower value of evidence and cannot 
determine causality, whereas longitudinal studies and randomized interventional studies in 
particular provide a high level of evidence. 
Both study I and study III show a correlation between metabolic risk factors and fat cell size 
and lipolysis respectively. Longitudinal studies involving weight changes and visceral 
adipose tissue changes would be of interest. Unfortunately, as mentioned before, they are 
difficult to perform due to the limited accessibility of visceral adipose tissue. Study II, a 
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longitudinal study, further strengthens the results seen in study I, namely that subcutaneous 
fat cell size could have an impact on insulin sensitivity.      
The design of study IV offers several strengths. Study IV was designed as a randomized 
double blinded controlled trial, i.e. all subjects and staff who participated in data collection 
were blinded for group allocation. The study population size was determined with a power 
calculation based on the primary outcome measure. Both the primary and secondary outcome 
measures were predetermined.  
5.1.2 Selection bias and non-completers 
All patients in the presented studies had visited a physician for referral to a surgical unit 
where they had been accepted for gastric bypass operation. The fact that they had sought 
medical care for their overweight may indicate that they were more concerned about their 
health than obese subjects in general. Subjects who were treated with insulin, warfarin or had 
a severe ongoing psychiatric disorder were excluded in these studies which could have led to 
a more healthy study population than a random sample of obese women in general. This 
might partially explain the low cholesterol levels before operation (4.9±0.9 mmol/l), when 
compared to women in a population based study in Sweden.
82
 All factors mentioned above 
might have resulted in a selection bias.  
Comparisons in study IV were made with per protocol analyses instead of intention to treat 
analysis since the gastric bypass operation leads to large differences in all parameters 
between the examinations before and after surgery. The subjects that for some reason did not 
complete the study had a higher baseline BMI (46.1 kg/m
2
 compared to 42.9 kg/m
2
 p= 0.013) 
compared to subjects that completed the study protocol which could have affected the results. 
However, there was no statistical difference between the number of non-completers in the 
study groups.         
5.1.3 Gender  
More obese women than men are trying to lose weight,
83
 and approximately 75% of the 
patients that undergo gastric bypass operation are women.
84
 We therefore chose to include 
only women since it would have been difficult to include enough male subjects to get power 
in study IV. This affects the generalizability of the results.  
We have not taken into account whether the subjects were pre- or postmenopausal, even 
though it has been shown that post-menopausal women have an increased risk of developing 
the metabolic syndrome independently of age.
85
 In fact, obese men have a more disturbed 
metabolic profile than obese pre-menopausal women but this risk reduction in women is 
abolished after menopause, as discussed.
86
 In addition, we did not take into account which 
part of the menstrual cycle the premenopausal women were. However, it has been shown that 
the menstrual cycle has no effect on insulin sensitivity.
87
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5.1.4 Exercise 
Weight reduction induced by exercise and changes in diet leads to a decrease in subcutaneous 
fat cell size, where the decrease preferentially is seen in the abdominal depot over the gluteal 
depot.
88
 Exercise seems to augment the effects of catecholamines and insulin on adipose 
tissue, as reviewed.
89
 We cannot exclude that the subjects´ degree of physical activity might 
have had an effect on our results as we did not adjust for that.  
5.1.5 Nicotine use 
Smoking induces release of noradrenaline and adrenaline and lead to increased levels of 
glycerol.
90
 In humans, using microdialysis technique in adipose tissue, systemically 
administered nicotine has been shown to induce lipolysis, probably by inducing release of 
catecholamines that stimulate β-adrenoreceptors, and also activating lipolysis through a 
nicotinic receptor.
91
 This indicates a clear effect of nicotine on lipolysis. However, in another 
study using microdialysis for in situ measurements of glycerol release from adipose tissue 
following smoking, no increased glycerol levels could be detected.
92
 We did not take 
smoking habits into account when we analyzed our results in study III and cannot exclude 
that this might have had an impact on our results.    
5.1.6 Methodological considerations 
5.1.6.1 Hyperinsulinemic euglycemic clamp 
Even though the hyperinsulinemic euglycemic clamp is considered to be the gold standard for 
measurement of whole body insulin sensitivity there are some methodical considerations to 
be made to optimize the accuracy of the procedure. The cohort that we studied constituted of 
both severely obese but also lean subjects after weight reduction. To measure whole body 
glucose disposal during the clamp, hepatic glucose production needs to be suppressed, 
otherwise less glucose is needed to maintain euglycemia and the glucose disposal rate will 
become falsely low. Traditionally an insulin infusion rate of 40 mU / m
2
 per minute or 
1mU/kg per minute is used during a hyperinsulinemic euglycemic clamp. However, based on 
previous experiences with our own obese subjects and a study by Prager et al,
93
 we concluded 
that this concentration would be inadequate in our severely obese population to suppress 
hepatic glucose output before weight reduction. Instead, we decided to use an insulin 
concentration of 120 mU/m
2
 which had been proved to be sufficient for our population.
93
 We 
used the body surface area instead of body weight for insulin infusion rate since the infusion 
rate of insulin per kilo becomes very high in obese subjects. However, the achieved insulin 
levels in our studies are sufficient to inhibit glucose release from the liver.
93
 
We had significantly higher serum insulin levels during our clamp in the obese subjects 
compared to subjects after weight reduction and this would have been even more pronounced 
if we had adjusted the insulin infusion rate for body weight instead of body surface area. The 
higher insulin levels before bariatric surgery might be due to decreased clearance/degradation 
of insulin in obesity, as reviewed.
94
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One way of solving the problem of hepatic glucose production when measuring whole body 
insulin sensitivity with hyperinsulinemic euglycemic clamp without using our high insulin 
concentrations could have been to use radiolabeled glucose in the infusion. Unfortunately we 
did not have that opportunity at our lab. 
5.1.6.2 Differences between hyperinsulinemic euglycemic clamp and HOMA-IR  
In study II, changes in fat cell size correlated with changes in whole body glucose disposal 
rate. However, changes in fat cell size (or changes in fat mass in different depots) did not 
correlate with changes in fasting insulin, fasting glucose or HOMA-IR (p= 0.15-0.52). The 
reason behind the differences in correlation between subcutaneous fat cell size, whole body 
insulin resistance and hepatic insulin sensitivity is unclear, but FFA might be involved. Free 
fatty acids have been shown to inhibit glucose disposal during hyper- and euglycemic 
hyperinsulinemia.
26, 95, 96
 Free fatty acids also induce insulin resistance in muscle by reduction 
of glucose transport and phosphorylation of glucose.
25
 Nielsen and colleagues showed that 
upper body subcutaneous adipose tissue is the main contributor of systemic FFA (~70%).
97
 
Visceral adipose tissue contribution to hepatic FFA delivery has been shown to be about 5-
10% in lean, 20-30% in obese and in some individuals up to 50%.
97
 However, our study 
group had a higher BMI than the obese in the study of Nielsen and colleagues,
97
 hence our 
cohort may have an even larger contribution of hepatic FFA from visceral adipose tissue. 
Differences in origin of free fatty acids delivered to the liver and muscle may offer a partial 
explanation to the discordant correlations of changes in subcutaneous fat cell size, hepatic- 
and whole body insulin sensitivity.   
5.1.6.3 Isolation of fat cells  
The abdominal subcutaneous fat biopsy is obtained by needle aspiration whereas the visceral 
fat biopsy is obtained by surgical excision. These methods do not result in any differences 
when examining adipose tissue characteristics according to a recent study.
98
   
Some investigations have found two distinct pools of fat cell sizes in the same subject 
whereof one pool consists of very small fat cells.
99, 100
 Surprisingly, a pool of very small fat 
cells have been found in subjects with adipose inflammation and insulin resistance
99, 101
 
These very small fat cells, with a diameter of 20-50 µm might be missed with the method we 
used to isolate fat cells.
102
 We can therefore not exclude that this pool of very small fat cells, 
if it exists, could have had an impact on our results. However, the very small “fat cells” have 
only been found by one group of investigators and their existence has been questioned. The 
very small fat cells could very well be lipid droplets produced as artefacts during preparation 
of fat cells, or a release from large fat cells undergoing cell death.   
5.1.6.4 Expression of lipolysis rate 
In study III, we choose to express lipolysis rate as µmol glycerol released/10
7
 cells/ 2 hours. 
However, there is no consensus how to express glycerol release from fat cells as a measure of 
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lipolysis. Both glycerol release /weight unit, glycerol/number of cells, or as a ratio of 
hormone stimulated/baseline lipolysis have been used previously.  
5.1.6.5 Measurement of body fat mass by DEXA 
DEXA has been used to evaluate body fat mass for some decades. It is relatively accurate 
compared with the absolute method (i.e. under water weighing), widely accessible and only 
exposes the subject to a minimal amount of radiation. As mentioned before, the accuracy of 
DEXA (with the Corescan feature) to estimate visceral adipose tissue in the android region is 
very high (r
2
=0.96).
60
 EVAT has also been shown to correlate with the size of the removed 
omentum in this cohort (r= 0.48 p= 0.0038).
103
 From the formula used by the DEXA software 
we calculated ESAT as total android fat mass minus EVAT. When we used this calculation 
we presumed that the values of EVAT and android fat mass were valid.  
5.1.6.6 Effects of omentectomy in study II 
Study II included subjects from study IV and these subjects had undergone RYGB with or 
without removal of the greater omentum. All analyses done in study II were also performed 
separately on the omentectomy group and no significant clinical differences in results were 
seen between the omentectomy group and the whole group.  
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6 CONCLUSION 
This thesis aimed to study two intrinsic adipose tissue characteristics, fat cell size and 
lipolysis, and their depot specific correlations with insulin resistance and dyslipidemia. In 
addition, the aim was to evaluate the potential positive metabolic effects of removing a large 
portion of visceral adipose tissue.  
Study I showed that in obese women, fat cell size correlated with the metabolic phenotype. 
The influence seems to be region specific. Large visceral fat cell size is more strongly 
correlated with dyslipidemia whereas large subcutaneous fat cell size correlates with insulin 
resistance. Obese women with hyperplasia in both regions have a more beneficial metabolic 
profile than those with combined hypertrophy. However, no causal relationships can be 
proved in this cross sectional study.  
Study II showed that a decrease in subcutaneous fat cell size rather than a decrease in fat 
mass per se is associated with improved insulin sensitivity after marked weight reduction. 
This prospective study strengthens the hypothesis that changes in intrinsic adipose tissue 
characteristics are more important for metabolic improvement following weight loss than 
decrease in fat mass per se. 
Study III evaluated the relative roles of subcutaneous and visceral fat cell lipolysis for 
cardiovascular risk factors in obesity. Visceral but not subcutaneous adipocyte triglyceride 
mobilization correlated with dyslipidemia, insulin resistance and estimated liver fat as well as 
the metabolic syndrome.  
Study IV investigated the potential additional positive metabolic effects of performing 
gastric bypass operation in conjunction with omentectomy compared to traditional gastric 
bypass operation. No such additional positive metabolic effects were seen on insulin 
resistance, blood lipids or weight reduction.  
In summary, the studies in this thesis highlight potential depot specific correlations 
between fat cell size, lipolysis and cardiovascular risk factor profile. Furthermore, 
changes in subcutaneous fat cell size, independently of a decrease in subcutaneous fat 
mass, correlate with improvement of insulin resistance following weight loss. A mere 
removal of a substantial part of the visceral fat depot does not enhance improved 
metabolic outcome after gastric bypass operation. The results in this thesis show that 
adipose characteristics are important for metabolic complications in obesity. 
Furthermore, it strengthens the hypothesis that intrinsic changes in adipose tissue are 
important for positive effects associated with weight reduction.  
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7 FUTURE PERSPECTIVES 
The results in this thesis generated some new interesting research questions that we will try to 
answer in the future.  
Can fat cell size be used as a prognostic factor for improvement of metabolic factors 
following bariatric surgery? 
The indication for bariatric surgery today is based on BMI both for obese subjects
104
 and 
subjects with type 2 diabetes.
105, 106
 However, baseline BMI does not predict the effect of 
bariatric surgery in terms of remission of diabetes, mortality, cardiovascular events or cancer 
according to the Swedish obesity study, as reviewed.
24
 Another study has shown that 
preoperative BMI does not predict improvement of hyperglycemia.
13
 Therefore it has been 
suggested that the indications should be modified and more importance should be given to 
metabolic variables and less to BMI.
24
 We currently investigate in a longitudinal study if 
subcutaneous fat cell can be used as a predictor of improved insulin sensitivity following 
weight reduction. The caveat with fat cell size as a predictor is that it demands a fat biopsy 
which is not convenient to use in a daily clinical setting. However, our group recently 
identified a transcription factor, early B cell factor (EBF-1) that is produced in adipocytes 
with reduced expression in adipose hypertrophy.
107
 EBF-1 is also negatively associated with 
lipolysis and down regulated after stimulation with TNFα in vitro.107 Although it is much too 
early to label EBF-1 as a prognostic factor it illustrates that there are signal substances 
produced in adipose tissue that in the future may be used in clinical practice as risk factor 
markers.    
What happens with fat cell size, insulin sensitivity and lipid status following weight regain? 
Subjects that decrease in weight actually have smaller fat cells than subjects with the same 
BMI that have been weight stable over time.
108
 However, as mentioned before, it is very 
difficult to maintain a weight reduced state over time,
109
 and subjects that lose weight tend to 
regain at least some weight.
24, 110
 It would be very interesting to see what happens with fat 
cell size and the metabolic profile following weight regain.    
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING  
Fetma är en känd riskfaktor för utveckling av insulinresistens och blodfettsrubbningar som i 
sin tur kan leda till hjärtinfarkt och stroke. Fettvävens egenskaper har också visat sig ha 
betydelse då dessa komplikationer uppkommer.  
Syftet med denna avhandling var trefaldigt. Dels att studera sambandet mellan fettcellernas 
storlek och insulinresistens och blodfettsrubbningar (studie I och studie II). Dessutom att 
studera fettcellernas förmåga att bryta ner fett (lipolys) och dess eventuella koppling till 
insulinresistens och blodfettsrubbningar (studie III). Vi undersökte vidare om det fanns 
skillnader i sambandet mellan dessa funktioner beroende på om fettet satt under huden 
(subkutant fett) eller kring tarmarna (visceralt fett) (studie I och studie III). Slutligen 
studerade vi om borttagande av en stor del av fettet kring tarmarna (omentektomi) i samband 
med gastric bypassoperation gav positiva metabola effekter jämfört med endast gastric 
bypassoperation (studie IV).  
Alla försökspersoner i avhandlingen ingick i en grupp av 81 kvinnor som genomgick gastric 
bypassoperation för att gå ner i vikt. Vid gastric bypassoperation kopplas matstrupen direkt 
till tunntarmen så att maten aldrig passerar magsäcken.  I studie I och studie III användes 
resultat från en undersökning som gjordes före operationen, medan studie II och studie IV 
även inkluderade en undersökning 2 år efter gastric bypassoperationen.  
Fettmängden i kroppen och på olika lokalisationer mättes med hjälp av bentäthetsmätare 
(DEXA, Dual-energy x-ray absorptiometry, som mäter mängden fett som ett bifynd). För att 
mäta insulinkänsligheten gavs försökspersonerna en förutbestämd mängd insulin. Sedan 
mättes hur mycket sockerlösning patienten behövde få för att upprätthålla en normal 
blodsockernivå (hyperinsulinemisk euglykemisk clamp). Mängden tillfört socker till blodet 
användes som ett mått på insulinkänslighet. Blodfetter mättes. Fettvävsprov togs både från 
fettet under huden samt det inre bukfettet. Storleken på fettcellerna bestämdes och även 
fettcellernas förmåga att bryta ner lagrat fett (lipolys) mättes.  
Studie I visade att större fettceller i underhudsfettet korrelerar med en ökad insulinresistens, 
vilket kan leda till utveckling av typ 2 diabetes. Större fettceller i fettet kring tarmarna 
korrelerar med både ökad insulinresistens och högre blodfetter. Personer med små fettceller i 
båda regionerna har mindre risk för typ 2 diabetes och blodfettsrubbningar än personer med 
stora fettceller oberoende av fettmängd. 
Studie II visade att förändringar i fettcellsstorlek i samband med viktnedgång korrelerar med 
förbättrad insulinkänslighet. Förändringen i subkutan fettcellstorlek var viktigare för 
förbättrad insulinkänslighet än minskningen av mängden fett. 
Studie III visade att förmågan att bryta ner fettsyror i fettet runt tarmarna korrelerade med 
ökad insulinresistens och högre blodfetter (kolesterol, triglycerider, LDL kolesterol). Något 
sådant samband fanns inte i underhudsfettet.    
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Studie IV var konstruerad som en randomiserad dubbel blind studie, där patienterna lottades 
till gastric bypassoperation med eller utan borttagande av omentfettet. Det vill säga, varken 
patienterna eller de som genomförde undersökningarna var medvetna om vilken grupp 
patienterna tillhörde. Studien visade att borttagande av en stor del av det inre bukfettet inte 
ger några förstärkta positiva effekter avseende förbättrad insulinresistens eller förbättrade 
blodfetter.  
Sammanfattningsvis visar studierna i avhandlingen att egenskaper i fettväven, såsom 
cellstorlek och lipolys, har olika påverkan på insulinresistens och blodfetter beroende på var 
fettet är lokaliserat (under huden eller vid tarmarna). Dessutom verkar förändringar i 
fettcellernas storlek i underhudsfettet, oberoende av förändringar i fettmängd, vara viktiga för 
förbättrad insulinkänslighet efter viktnedgång. Att kirurgiskt ta bort en stor del av fettet kring 
tarmarna i samband med överviktskirurgi verkar inte ha några positiva effekter jämfört med 
endast överviktskirurgi. Resultaten i avhandlingen talar för att fettvävens egenskaper, såsom 
fettcellsstorlek och lipolysförmåga, oberoende av fettmängd, är viktiga för utveckling av 
metabola komplikationer. Dessutom verkar en minskning av fettcellernas storlek vara en 
viktig förutsättning för positiva effekter på insulinkänslighet och blodfetter vid viktnedgång.  
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